Omecamtiv-mecarbil-CK-1827452-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁
Omecamtiv-mecarbil-CK-1827452-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁
Omecamtiv-mecarbil-CK-1827452-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEOmecamtiv mecarbilCat. No.: HY-14233CAS No.: 873697-71-3Synonyms: CK-1827452分式: CHFNO分量: 401.43作靶點(diǎn): Myosin作通路: Cytoskeleton儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (124.55 m

2、M; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.4911 mL 12.4555 mL 24.9109 mL5 mM 0.4982 mL 2.4911 mL 4.9822 mL10 mM 0.2491 mL 1.2455 mL 2.4911 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄清的儲備液,再依次添加助溶?為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲備液

3、可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.23 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.23 mM); Clear solution3. 請依序添加每種溶劑: 10% DMSO 90% corn oil1/2 Master of Small Molec

4、ules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (6.23 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Omecamtiv mecarbil肌肌球蛋激活劑。體外研究 Omecamtiv mecarbil (10 M) reduces the maximal ATPase (kcat) 4.5-fold and dramatically reduces the actinconcentration at which ATPase is half-maximal (KATPase) 30-fold. The Ome

5、camtiv mecarbil-inducedinhibition of the actin-activated ATPase is evaluated in a concentration-dependent manner to determine theEC50 (0.52 0.10 M). Omecamtiv mecarbil does not change the overall actin affinity. Omecamtiv mecarbiltraps a population of myosin heads in a weak actin affinity state with

6、 slow product release. Omecamtivmecarbil can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay 3.體內(nèi)研究 Omecamtiv mecarbil (100-1000 ng/mL) demonstrates concentration-dependent increases in FS inSpragueDawley rats model. Omecamtiv mecarbil demonstrates good PK paramet

7、ers in both rats(SpragueDawley) and dogs (Beagle) with clearances of 22 and 7.2 mL/min/kg, volumes of 3.5 and 3.6 L/kg,and bioavailabilities (F%) of 100 and 80%, respectively 1. Omecamtiv mecarbil does not affect thephosphorylation status of myofilament proteins in both WT and KO hearts as shown by

8、the absence ofsignificant differences between pre and post Omecamtiv mecarbil samples within WT and KO groups, oraffect the force generation at maximal Ca2+ activation (pCa 4.5) in any of the groups. Omecamtiv mecarbilincreases the responsiveness of the cardiac myofilaments to Ca2+ at submaximal Ca2

9、+-activations 2.REFERENCES1. Morgan BP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett.2010 Aug 20;1(9):472-7.2. Mamidi R, et al. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skin

10、ned myocardium lackingcardiac myosin binding protein-C. J Mol Cell Cardiol. 2015 Aug;85:262-72.3. Swenson AM, et al. Omecamtiv Mecarbil Enhances the Duty Ratio of Human -Cardiac Myosin Resulting in Increased CalciumSensitivity and Slowed Force Development in Cardiac Muscle. J Biol Chem. 2017 Mar 3;292(9):3768-3778.McePdfHeightCaution: Product has not been fully val

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論